Peptide-based cancer vaccines

Current Opinion in Immunology

Volumn 8, Issue 5, 1996, Pages 651-657

  Melief, Cornelis J M ^a   Offringa, Rienk ^a   Toes, RenéE M ^a   Kast, Martin W ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; PEPTIDE; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; HUMAN; REVIEW; T LYMPHOCYTE; TUMOR MODEL;

EID: 0030272236     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80081-1     Document Type: Article

References (66)

1. Sercarz EE, Lehmann PV, Ametani Benichou G, Miller A, Moudqil K. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol. 11:1993;729-766.
2. Ochoa A, Longo DL. Alteration of signal transduction in T cells from cancer patients. De Vita VT, Hellman S, Rosenberg SA. Important Advances in Oncology. 1995;43-54 JB Lippincott Company, Phildelphia.
3. Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res. 58:1992;143-175.
4. Nanda Nk, Sercarz EE. Induction of anti-self immunity to cure cancer. Cell. 82:1995;13-17.
5. Seung LP, Rowley DA, Dubey P, Schreiber H. Synergy between T cell immunity and inhibition of paracrine stimulation causes tumor rejection. of special interest Proc Natl Acad Sci USA. 92:1995;6254-6258 Paracrine factor produced by tumor cells counteracts tumor eradication by T lymphocytes. The factor attracts granulocytes that make the tumor cells grow faster, outsmarting the T lymphocytes.
6. Parangi S, O'Reilly M, Christophori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D. Anti-angiogenic therapy of transgenic mice impairs de novo tumor growth. of special interest Proc Natl Acad Sci USA. 93:1996;2002-2007 Antiangiogenic therapy may eventually be used synergistically with T cell therapy. Who wants to try it first?
7. Melief CJM, Kast WM. Prospects for T cell immunotherapy of tumors by vaccination with immunodominant and subdominant peptides. Vaccines against Virally Induced Cancers (Ciba Symposium 189). 1994;97-102 John Wiley & Sons, Chichester.
8. Melief CJM, Kast WM. T cell immunotherapy by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev. 145:1995;167-177.
9. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein: coordinate up-regulation of peptide transporters and HLA class I antigen expression. of special interest Eur J Immunol. 25:1995;1374-1384 EBV LMP may restore some of the antigen processing and presentation defects in Burkitt's lymphoma cells.
10. Levitskaya J, Coram M, Levitsky V, Imveh S, Steiger Wald-Mullen PM, Klein G, Kurilla MG, Masucci MG. inhibition of antigen processing by the internal repeat region of the EBV EBNA-1 antigen. of outstanding interest Nature. 375:1995;685-688 A starting stratery of the viral gene product. Cis-acting failure of MHC class I processing and presentation of EBNA-1 CTL epitopes by an EBNA-1 internal repeat region.
11. + healthy donors.
12. Kast WM, Brandt RPM, Sidney J, Drifthout JW, Kubo RF, Grey HM, Melief CJM, Sette A. A Role of HLA-A motifs in identification of potential CTL epitopes in human paillomavirus type 16 E6 and E7 proteins. J Immunol. 152:1994;3904-3912.
13. *0201-binding peptides. This demonstrates that such patients do not react to all possible viral epitopes and that vaccination might be beneficial for the large majority of patients.
14. Boon T, Van der Bruggen P. Human tumor antigens recognized by T lymphocytes. of outstanding interest J Exp Med. 183:1995;725-729 One of the first clinical vaccination trials against a tumor associated self antigen shows that T cell tolerance can be broken by deliberate vaccination. No clinical benefit was observed in this study, however.
15. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia CEA vaccine. of outstanding interest J Natl Cancer Inst. 87:1995;982-993 One of the first clinical vaccination tirals against a tumor-associated self antigen shows that T cell tolerance can be broken by deliberate vaccination. No clinical benefit was observed in this study, however.
16. *0201. of special interest Int J Cancer. 61:1995;389-396 CTL epitope identified mutant p21 Ras presented by HLA-A 0201.
17. + responses.
18. Disis ML, Smith HW, Murphy AE, Chen W, Cheever MA. in vitro generation of human CTLs specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res. 54:1994;1071-1076.
19. Houbiers JGA, Nijman HW, Van der Burg SH, Drijfhout JW, Kenemans P, Van de Velde CJM, Brand A, Momberg F, Kast WM, Melief CJM. in vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53. Immunology. 23:1993;2072-2077.
20. Nijman HW, Van der Burg SH, Vierboom MPM, Houbiers JGA, Kast WM, Melief CJM. p53, a potential target for tumor-directed T cells. Immunol Lett. 40:1994;171-178.
21. BCR-ABL protein by human T cells. Leukemia. 9:1995;1344-1348.
22. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. of outstanding interest Blood. 1996; First demonstration that T cells directed against a chromosomal breakpoint peptide recognize human cancer cells.
23. Dahl AM, Beverly P, Stauss HJ. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity CTLs that recognise naturally processed protein. of outstanding interest J Immunol. 1996; Autoreactive CTLs raised in mice against an mdm2 peptide lyse cells bearing processed mdm2.
24. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. of outstanding interest Proc Natl Acad Sci USA. 92:1995;11993-11997 CTLs raised against in HLA-A2-transgenic mice against a wild-type p53 peptide can lyse human tumor cells.
25. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol. 8:1996;75-81.
26. Den Haan JMM, Sherman NE, Blokland E, Huckzo E, Koning F, Drifthout JW, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E. Identification of graft versus host disease associated human minor histocompatibility antigen. of outstanding interest Science. 268:1995;1478-1480 First molecular identification of a human minor histocompatibility antigen by tandem mass spectrometry.
27. Wang W, Meadows LR, Den Haan JMM, Sherman NE, Chen Y, Blokland E, Shabanowitz J, Agulnik AI, Hendrikson RC, Bishop CE, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. of special interest Science. 269:1995;1588-1590 Second human minor histocompatibility antigen characterized molecularly: the long sought after 'male-antigen'. Human minor H antigens could serve as target antigent for cancer therapy under various circumstances.
28. Goldberg AL, Gaczynska M, Grant E, Michalik M, Rock KL. Functions of the proteasome in antigen presentation. Cold Spring Harb Symp Quant Biol. 50:1995;47-61.
29. Niedermann G, Butz S, Ihlenfeldt HG, Grimm R, Lucchiari M, Hoschützki H, Jung G, Masier B, Eichmann K. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. of special interest Immunity. 2:1995;289-299 This paper, along with [30], documents that CTL epitope hierarchy is strongly influenced by proteasome cleavage patterns.
30. Eggers M, Boes-Fabian B, Ruppert T, Kloetzel PM, Koszinowski UH. The cleavage preference of the proteasome governs the yield of antigenic peptides. of special interest J Exp Med. 182:1995;1865-1870 See annotation [29].
31. Ossendorp F, Eggers M, Neisig A, Ruppert T, Groettrap M, Sijts A, Mengedé E, Kloetzel PM, Neafjes J, Koszinowski UH, Melief CJM. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation of outstanding interest Immunity. 1996; Demonstrating that a virus-encoded dominant CTL epitope in a tumor can be destroyed prematurely by mutation at a single amino acid position in the epitope that results accelerated proteasomal degradation.
32. Neisig A, Roelse J, Sijts AJAM, Ossendorp F, Eeltkamp MCW, Kast WM, Melief CJM, Neefjes JJ. Major difference in TAP dependent translocation of MHC presentable peptides and the effect of flanking sequences. of special interest J Immunol. 154:1995;1273-1276 Demonstration that TAP-dependent translocantion can sometimes depend on amino acids flanking the actual MHC binding epitope.
33. Schulz M, Zinkemagel RM, Hengartner H. Peptide-induced anti-viral protection by cytotoxic T-cells. Proc Natl Acad Sci USA. 88:1991;991.
34. Kast WM, Roux L, Curren J, Blom HJJ, Voordouw AC, Meloen RH, Kolakovsky D, Melief CJM. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with an unbound peptide. Proc Natl Sci USA. 88:1991;2283-2287.
35. Kast WM, RMP Brandt, Melief CJM. Strict peptide length is not required for the induction of the cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination. Eur J Immunol. 23:1993;1189-1192.
36. Cole GA, Hogg TL, Woodland DI. The MHC class I restricted T-cell response to Sendai virus in C57BL/6 mice: a single immunodominant epitope elicits an extremely diverse repertoire of T-cells. Int Immunol. 6:1994;1767-1775.
37. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, De Jongh BM, Drijfhout JW, Ter Schegget J, Melief CJM, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 23:1993;2242-2249.
38. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature. 369:1994;67-71.
39. Mandelboim O, VAdai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G, Eisenbach L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. of outstanding interest Nat Med. 1:1995;1179-1183 The peptide identified in [38] can be used as a peptide vaccine to cause regression of metastatic tumors.
40. dVitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Urze J, Barholomeuz R, Chestnut RW. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection I: induction of a primary cytotoxic T lymphocyte response in humans. of outstanding interest J Clin Invest. 95:1995;341-345 First application of an MHC class I binding peptide vaccine in humans. An HBV-derived peptide induces a vigorous CTL response in healthy volunteers capable of lysing HBV-infected target cells.
41. Schild H, Norma M, Deres K, Falk K, Rötschke O, Wiesmüller KH, Jung G, Rammensee HG. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J Exp Med. 174:1991;1665-1669.
42. Aichele P, Brduscha-Riem, Zinkernagel RM, Hengartner H, Pricher H. T cell priming versus T-cell tolerance induced by synthetic peptides. of outstanding interest J Exp Med. 182:1995;261-266 High dose peptide in IFA, repeatedly injected intraperitoneally in mice, cause tolerance rather than immunity.
43. Aichele P, Kybarz D, Ohashi PS, Odermatt B, Zinkernagel RM, Hengartner H, Pircher H. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc Natl Acad Sci USA. 91:1994;444-448.
44. Kast WM, Offringa R, Peters PJ, Voordouw A, Meloen RH, Van der Eb AJ, Melief CJM. Eradication of adenovirus E1 induced tumors by E1A-specific cytotoxic T lymphocytes. Cell. 59:1989;603-614.
45. Toes REM, Offringa R, Blom RJJ, Brandt RMP, Van der Eb AJ, Melief CJM, Kast WM. An adenovirus type 5 early region 1 B-encoded CTL epitope mediating tumr eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol. 154:1995;3396-3405.
46. Toes REM, Blom RJJ, Offringa R, Kast WM, Melief CJM. Functional deletion of tumor-specific CTLs induced by peptide vaccination can lead to the inability to reject tumours. of outstanding interest J Immunol. 156:1996;3911-3918 CTL tolerance associated with enhanced tumor outgrowth can also be achieved by a single injection of low dose immunodominant peptide in IFA Excellent protection is achieved if the same epitope is presented by Ads.
47. Toes REM, Offringa R, Blom RJJ, Melief CJM, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. of special interest Proc Natl Acad Sci USA. 1996; Same results as in [49] but with a different CTL epitope.
48. of outstanding interest Matzinger P. Tolenrance, danger, and the extended family. Annu Rev Immunol. 12:1994;991-1045.
49. of special interest Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 183:1996;283-287 Dendritic cells are a potent delivery system in CTL epitope vaccination.
50. of outstanding interest Mayordomo JI, Zorma T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJM, Ildstad ST, Kast WM, Deleo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-lumour immunity. Nat Med. 1:1995;1297-1302 Peptide-pulsed DCs can even eradicate (small) established tumours.
51. of special interest Zitvogel L, Mayordomo JI, Tjandrawan T, Deleo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumours with peptide-pulsed dendritic cells: dependence on T-cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 183:1996;87-97 Nonidentified peptides, eluted from MHC class I molecules on tumors at low pH, can serve as an efficient preventive vaccine, if delivered on activated DCs.
52. + T-cells. Proc Natl Acad Sci USA. 91:1994;3171-3175.
53. of outstanding interest Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasany PM, Lotze MT, Storkus WJ, Appella E, Deleo AB. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med. 183:1996;1357-1365 Both mutant and wild-type p53 MHC class I binding peptides delivered on DCs protect against tumor outgrowth.
54. of outstanding interest Marchand M, Wegmants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, VanWijck R, Humblet Y, et al. Tumore regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int CAncer. 63:1995;883-885 Free peptides delivered without adjuvant to patients with metastatic melanoma cause complete remission in two patients.
55. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergrin MT, Ozols J, Meehan J, Mauri F. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA. 92:1995;8078-8082.
56. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor associated antigen. J Immunol. 154:1995;4685-4692.
57. McCabe BJ, Irvine KR, Nishimura MI, Yang JC, Spiess PJ, Shulman EP, Rosenberg SA, Restifo NP. Minimal determinant expressed by recombinant vaccinia virus elicits therapeutic anti tumor cytolytic T lymphocyte responses. Cancer Res. 55:1995;1741-1747.
58. + CTLs.
59. Whitton JL, Sheng N, Oldstone MBA, McKee TA. A 'string of-beads' vaccine, comprising linked minigenes, confers protection form lethal-dose virus challenge. J Virol. 67:1993;348-352.
60. of special interest Weidt G, Deppert W, Buchhop S, Dralle H, Lehmann-Grube F. Anti-viral protective immunity induced by major histocompatibility complex class I molecule restricted viral T-lymphocyte epitopes inserted in various positions in immunologically self and nonself proteins. J Virol. 69:1995;2654-2658 First demonstration of protective effect of CTL epitope string-of-beads protein construct.
61. + cytotoxic T-cells: implications for vaccine design. Proc Natl Acad Sci USA. 92:1995;5845-5849 Stirng-of-beads CTL epitope design for EBV vaccination purposes.
62. Bevan MJ. Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med. 182:1995;639-641.
63. + cytolitic T cell responses. J Exp Med. 182:1995;1663-1671.
64. + T lymphocytes by vaccination with nonliving bacteria. Proc Natl Acad Sci USA. 92:1995;12389-12393.
65. of special interest Toes REM, Blom RJJ, Van der Voort EIH, Offringa R, Melief CJM, Kast WM. Protective anti-tumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res. 1996; Protective vaccination induced by immunication with completely allogeneic tumor cells is associated with CTL memory to viral antigens processed by host APCs.
66. Pardoll DM, Beckerleg AML. Exposing the immunology of naked DNA vaccines. Immunity. 3:1995;165-169.